Chemotherapy enhances cancer vaccine efficacy and expands stem-like TCF1(+)CD8(+) T cells.

Chemotherapy, especially CarboTaxol, boosts cancer vaccine effectiveness by expanding stem-like TCF1(+)CD8(+) T cells, improving tumor control and survival.

• Why it matters: Understanding how chemotherapy enhances vaccine responses can optimize combination therapies for cancer treatment, addressing a key gap in immunotherapy strategies.
• What they did: Researchers tested viral vector vaccines with chemotherapy regimens, finding that CarboTaxol and cyclophosphamide improve CD8+ T cell responses and act as immunological adjuvants, independent of tumor presence.
• The result: CarboTaxol induces early expansion of TCF1+ CD8+ T cells, a process essential for its adjuvant effect, and combining PD-1 blockade further enhances tumor control, supporting clinical evaluation of this triple therapy.